REYKJAVIK, Iceland, Dec. 18, 2013 /PRNewswire/ -- deCODE genetics, a global leader in analyzing and understanding the human genome, reported today in the journal Nature that mutations associated with an increased risk of schizophrenia and autism also affect cognition in individuals without the disease or intellectual disability. The research suggests that cognitive abnormalities are fundamental in schizophrenia, yet outward signs of the disease only manifest in a subset of carriers of the mutations.
“This study provides one of the first footholds into biochemical understanding of humans’ unique cognitive abilities,” said study lead author Kari Stefansson, M.D., Dr. Med., CEO of deCODE genetics. “At the same time, these results raise important questions as to why certain mutations impact some individuals more dramatically than others.”
Certain copy number variants (CNVs), one type of mutation, have been previously identified as strong risk factors for schizophrenia and autism, neuropsychiatric diseases which affect cognition. Researchers sought to understand what, if any, impact these CNVs may have on cognitive ability in disease-free carriers.
They administered neuropsychiatric tests to 1,268 individuals across four groups (schizophrenia patients, control carriers of neuropsychiatric CNVs, control carriers of other CNVs and population controls), and found that carriers of CNVs that predispose to neuropsychiatric disease have cognitive abilities between people without the CNVs and people with schizophrenia.
“Our results suggest that neuropsychiatric CNVs can be used as an instrument for further study of the cognitive abnormalities that characterize schizophrenia, because whether or not an individual develops this disease is likely related to the expression of these genes,” said Stefansson. “The findings also provide insight into which cognitive abilities put individuals at risk of developing schizophrenia and demonstrate that control carriers provide an opportunity to study cognitive abnormalities without the confounding effects of psychosis or medication.”
About deCODE
Headquartered in Reykjavik, Iceland, deCODE genetics is a global leader in analyzing and understanding the human genome. Using its unique expertise and population resources, deCODE has discovered genetic risk factors for dozens of common diseases ranging from cardiovascular disease to cancer. deCODE genetics is a subsidiary of Amgen. deCODE’s corporate information can be found at http://www.decode.com.
Media Contact:
Tom Langford
tom.langford@fkhealth.com
617-761-6775
SOURCE deCODE genetics
Help employers find you! Check out all the jobs and post your resume.
